The April 2026 Department of Justice order immediately moved FDA-approved marijuana products and those under state medical marijuana licenses into Schedule III of the Controlled Substances Act, effective late that month, while directing the DEA to begin an expedited administrative hearing on June 29, 2026, to consider broader rescheduling of all marijuana from Schedule I. This action responded to a December 2025 executive order emphasizing research access and followed the prior HHS scientific review recommending Schedule III placement. Traders are now focused on whether the hearing produces a final rulemaking that resolves the market before year-end deadlines, potential legal challenges to the process, and any further agency actions or congressional involvement that could accelerate or delay full implementation.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$760,009 Vol.
June 30
2%
December 31
26%
$760,009 Vol.
June 30
2%
December 31
26%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The April 2026 Department of Justice order immediately moved FDA-approved marijuana products and those under state medical marijuana licenses into Schedule III of the Controlled Substances Act, effective late that month, while directing the DEA to begin an expedited administrative hearing on June 29, 2026, to consider broader rescheduling of all marijuana from Schedule I. This action responded to a December 2025 executive order emphasizing research access and followed the prior HHS scientific review recommending Schedule III placement. Traders are now focused on whether the hearing produces a final rulemaking that resolves the market before year-end deadlines, potential legal challenges to the process, and any further agency actions or congressional involvement that could accelerate or delay full implementation.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions